Akira Kawai, Mikiya Ishihara, Tomoki Nakamura, Shigehisa Kitano, Shintaro Iwata, Kohichi Takada, Makoto Emori, Koji Kato, Makoto Endo, Yoshihiro Matsumoto, et al. Safety and Efficacy of NY-ESO-1 Antigen-specific T-cell Receptor Gene-Transduced T Lymphocytes in Patients with Synovial Sarcoma: A Phase I/II Clinical Trial. Clinical cancer research : an official journal of the American Association for Cancer Research. 2023
Mikiya Ishihara, Yoshihiro Nishida, Shigehisa Kitano, Akira Kawai, Daisuke Muraoka, Fumiyasu Momose, Naozumi Harada, Yoshihiro Miyahara, Naohiro Seo, Hiroyoshi Hattori, et al. A phase 1 trial of NY-ESO-1-specific TCR-engineered T-cell therapy combined with a lymph node-targeting nanoparticulate peptide vaccine for the treatment of advanced soft tissue sarcoma. International journal of cancer. 2023. 152. 12. 2554-2566
Satoshi Okumura, Mikiya Ishihara, Naomi Kiyota, Kimikazu Yakushijin, Kohichi Takada, Shinichiro Kobayashi, Hiroaki Ikeda, Makoto Endo, Koji Kato, Shigehisa Kitano, et al. Chimeric antigen receptor T-cell therapy targeting a MAGE A4 peptide and HLA-A*02:01 complex for unresectable advanced or recurrent solid cancer: protocol for a multi-institutional phase 1 clinical trial. BMJ Open. 2022. 12. 11. e065109-e065109
北嶋 貴仁, 志村 匡信, 奥川 喜永, 宮原 慶裕, 問山 裕二. 大腸癌患者における4-1BB,PD-1発現の臨床的意義の検討(The association between 4-1BB or PD-1 expressions and oncological outcomes in colorectal cancer patients). 日本癌学会総会記事. 2023. 82回. 608-608
腫瘍におけるNY-ESO-1発現と抗体反応はMAGE-A4ワクチン療法を受ける食道・頭頸部癌患者の予後不良を示す(NY-ESO-1 expression and antibody related to poor outcome in MAGE-A4-vaccinated esophageal and head/neck cancer patients)
(日本癌学会総会 2018)
ひとつのマウス自然発生肉腫に由来する免疫原性、血管新生能の異なる3クローンの樹立(Three clones derived from a spontaneous mouse sarcoma representing distinct immunogenicity and vasculogenic activities)
(日本癌学会総会 2018)
ヒト大腸がん組織に浸潤する腫瘍反応性CD8陽性T細胞の表現型および遺伝子解析(Phenotypic and genetic characteristics of tumor-reactive CD8+ T cells existing in human colorectal tumor tissue)
(日本癌学会総会 2018)
有望な遺伝子改変γδ T細胞を用いたがん免疫療法(Promising use of gene-modified γδ T cells for Cancer Immunotherapy)
(日本癌学会総会 2018)
Cytokine Release Syndrome and Tumor Responses in a First-in-Man Trial of a Novel Affinity-Enhanced TCR-Gene Transduced T Cell Transfer Targeting NY-ESO-1 Antigen
(American Society of Hematology (ASH) 2017)
